Randomised, Parallel-group, Double-blind Study of Systemic and Ocular Safety and Pharmacokinetics of BI 409306 in Patients With Schizophrenia, Alzheimer's Disease, and Age-comparable Healthy Volunteers
Active, no longer recruiting
Phase of Trial: Phase I
Latest Information Update: 30 Aug 2017
At a glance
- Drugs BI 409306 (Primary)
- Indications Alzheimer's disease; Schizophrenia
- Focus Adverse reactions
- Sponsors Boehringer Ingelheim
- 23 Aug 2017 Status changed from recruiting to active, no longer recruiting.
- 23 Feb 2017 Planned End Date changed from 1 May 2017 to 1 Aug 2017.
- 23 Feb 2017 Planned primary completion date changed from 1 May 2017 to 1 Aug 2017.